Immunomedics shares jump as Gilead agrees to a $21 billion buy deal

Shares of cancer drugmaker Immunomedics doubled after Gilead Sciences announced on Sunday that it will acquire the company for $21 billion, or $88 per share in cash.In pre-market trading on Monday, Im...